In the phase 3 RC48-C016 study, disitamab vedotin plus toripalimab significantly improved PFS and OS vs chemotherapy.

Timothy D. McClure, MD, discusses focal therapy with IRE, specifically highlighting its benefits and limitations compared with other treatment options.

In this interview, Tom Jayram, MD, offers insights into how BCG plus immune checkpoint inhibitors may redefine the treatment landscape in BCG-naïve NMIBC.

In this interview, Avani Desai, an MD candidate at the University of North Carolina in Chapel Hill, discusses findings from a study examining the public availability of parental leave policies across ...

"It is common for a payer to request patient records when submitting for a service with a category III code," write Jonathan Rubenstein, MD, and Mark Painter.

There was a wealth of important developments across urology in July 2025, with notable advancements in benign conditions such as stress urinary incontinence (SUI) and benign prostatic hyperplasia (BPH ...

In this interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, founder of the Fosnight Center for Sexual Health and medical advisor for Aeroflow Urology, outlines how pelvic floor ...

Jansen underscores the need for urologists to go beyond symptom treatment and focus on identifying root causes of testosterone deficiency.

Key Takeaways The STRIKE-001 trial evaluates KTX-2001, an NSD2 inhibitor, for mCRPC, with FDA clearance and collaboration with Bayer for darolutamide supply. The trial, managed by PCCTC, will enroll ...

PCNL showed superior stone clearance and patient-reported outcomes for stones larger than 15 mm compared to ureteroscopy. Ureteroscopy and shockwave lithotripsy had similar stone clearance rates, but ...

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact ...

Panelists discuss how NCCN guidelines provide a framework for selecting appropriate androgen deprivation therapy (ADT) regimens across different disease states, with combination therapies now being ...